As part of a drug discovery program under the leadership of Nobel Laureate Ferid Murad, M.D., Ph.D at the University of Texas Health Science Center at Houston, Dr. Nathan Bryan discovered a novel composition of matter from natural products that generated authentic Nitric Oxide (NO) gas, as well as activated endogenous endothelial NO production. These discoveries have led to five issued U.S. patents, and have been proven safe and effective in five published, randomized, placebo-controlled clinical trials.

NO is considered one of the most important molecules produced in the human body. It is responsible for maintaining the integrity of the cardiovascular system, normal blood pressure, and a host of other physiological activities. Recent discoveries have revealed a secondary pathway to endogenous NO production complimentary to the L-arginine nitric oxide synthase-derived NO. Through serial reduction of nitrate to nitrite and NO, this pathway can be therapeutically harnessed to provide a continuous source of NO independent of endothelial production, providing a unique and innovative opportunity to replete and recapitulate NO-based signaling.

AusTech’s patented technology provides a bi-phasic, exogenous source of NO while re-coupling the NO synthase enzyme to restore endogenous production of NO.  This orally disintegrating NO technology generates 25-30 ppm authentic NO gas over a 5-6 minute dissolution time. This exogenous NO begins to dilate blood vessels within 90 seconds and has a biological half-life of 6-8 hours. The second phase of the technology re-couples the NO synthase enzyme to restore endothelial production of NO by 15% within 4 hours. This technology does not cause tachyphylaxis as organic nitrates.

The one drug, one target model standard for active pharmaceutical ingredients does not apply to NO-based technologies, as NO is a labile gas with a very short half-life. Our unique NO delivery technology allows for safe and effective dosing that recapitulates NO-based signaling throughout the body. Due to the ubiquitous nature of NO, this technology has broad therapeutic value beyond hypertension. Our ongoing clinical trials in pulmonary hypertension, peripheral artery disease, pre-eclampsia, erectile dysfunction, and urea cycle disorders provide evidence on safety and efficacy in each of these therapeutic areas.